Abstract: A phenylalanine-glycine compound of formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described. The novel conjugate of the phenylalanine-glycine compound and the antitumor substance exhibits superior antitumor activity in comparison with the case wherein an antitumor substance is administered alone or as a mixture with phenylalanine.

Abstract: Azole derivatives (including stereoisomers and pharmaceutically acceptable salts) of the formula: ##STR1## wherein R.sub.1 and R.sub.2 each are H or C.sub.1 -C.sub.4 alkyl; R.sub.3 is H, OH, CN, halogen, haloalkyl, C.sub.1 -C.sub.4 alkyl or phenyl, and if there are two or more R.sub.3 groups, such R.sub.3 groups may be the same or different; n is an integer from 0 to 5; Y is N or CH; and X is O, S or NH have antimycotic and aromatase inhibitory activities. Compositions containing the azole derivatives and a method of treating mycosis and estrogen-dependent diseases by administering effective quantities of the azole derivatives are also disclosed.

Abstract: Resin compositions of improved dispersibility and mechanical properties are obtained by polymerizing a polymerizable compound (A), insitu in a melted thermoplastic resin (B), in the presence of a dispersant (C) reactive or compatible with at least one of the resin (B) and polymerizate of (A).Suitable dispersants include those represented by the general formula (1) or (2)R.sub.1 --L(X--M--X--L).sub.n X--M--R.sub.2 (1)R.sub.1 --L(X--M--X--L).sub.n --R.sub.2 (2)wherein R.sub.1 and R.sub.2 are groups, such as hydrocarbyl acyl, alkoxy, hydroxyl, mercapto, amino, epoxy, isocyanate, carboxylic, carboxylic anhydride, carboxylic halide and aldehyde groups; L and M are residues of a polymer having a number average molecular weight of about 500-about 3,000,000, the difference in solubility parameter between the residue L or M and the resin (B) or polymerizate of (A) being not more than 0.

Abstract: Azole derivatives (including stereoisomers and pharmaceutically acceptable salts) of the formula: ##STR1## wherein R.sub.1 and R.sub.2 each are H or C.sub.1 -C.sub.4 alkyl; R.sub.3 is H, OH, CN, halogen, haloalkyl, C.sub.1 -C.sub.4 alkyl or phenyl, and if there are two or more R.sub.3 groups, such R.sub.3 groups may be the same or different; n is an integer from 0 to 5; Y is N or CH; and X is O, S or NH have antimycotic and aromatase inhibitory activities. Compositions containing the azole derivatives and a method of treating mycosis and estrogen-dependent diseases by administering effective quantities of the azole derivatives are also disclosed.

Abstract: A polymer composite comprises about 5 to 95 parts by weight of a copolymer (A) selected from the group consisting of olefin/diene copolymer and ethylene/(meth)acrylic acid ester copolymer, and 5 to 95 parts by weight of a polyurethane resin (B), wherein the polyurethane resin is one which is synthesized in the melted copolymer in the absence of a compatibilizer, a composition for molding comprising such polymer composite and electroconductive fillers and its molded article, and rubber contacts. The polymer composite possesses the flexibility and durability equivalent to those of silicone rubber, has excellent injection molding property, can be made by a short manufacturing process, and can be manufactured inexpensively. The polymer composite of the invention, when used together with an electroconductive filler, is effectively applied as rubber contacts, that is, flexible electric connection members of electric products.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.

Abstract: Disclosed herein are the derivatives of substituted cephalosporanic acid represented by the formula (I): ##STR1## wherein R.sup.1 represents a 4-pyridylthiomethyl group, an alpha-aminobenzyl group, a cyanomethyl group or a 1-tetrazolylmethyl group; R.sup.2 represents a hydrogen atom, an acetoxy group or a (5-methyl-1,3,4-thiadiazol-2-yl)thio group; R.sup.3 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1, n is 0, 1 or 2 and the carboxyl group may have been converted to a salt or an ester thereof; p is 0, 1 or 2 and X represents carbon atom or nitrogen atom, and antibiotics comprising the derivatives of substituted cephalosporanic acid represented by the formula (I).

Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are a cephalosporin derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents a halogenoalkyl group, a salt and ester thereof, a process for producing the same, and a pharmaceutical composition and an antibacterial agent comprising the same.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, xylose, glucose, galactose, rhamnose and mannose, and .sup.2 R denotes hydrogen or methyl group, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are a derivative of a substituted cephalosporanic acid, represented by the formula (I): ##STR1## wherein p is 0, 1 or 2 and R.sup.1 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1; n is 0, 1 or 2 and the carboxyl group may have been converted to the salt or the ester thereof, and an antibiotic comprising a derivative of substituted cephalosporanic acid represented by the formula (I).

Abstract: Disclosed herein are 7-beta-[2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-(2-amino-1,3,4- thiadiazolyl-5-thiomethyl)-3-cepheme-4-carboxylic acid, salts thereof and pivaloyloxymethyl ester thereof, and a pharmaceutical composition containing the same as an active ingredient.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-L-rhamonoside or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.